Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A “Tail” of Two Cities: Fatality-based Modeling of COVID-19 Evolution in New York City and Cook County, IL

Joshua A. Frieman
doi: https://doi.org/10.1101/2020.08.10.20170506
Joshua A. Frieman
1Fermi National Accelerator Laboratory, P. O. Box 500, Batavia, IL 60510, USA
2Kavli Institute for Cosmological Physics, Department of Astronomy & Astrophysics, The University of Chicago, Chicago, IL 60637, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: frieman{at}fnal.gov
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

I describe SIR modeling of the COVID-19 pandemic in two U.S. urban environments, New York City (NYC) and Cook County, IL, from onset through mid-June, 2020. Since testing was not widespread early in the pandemic in the U.S., I rely on public fatality data to estimate model parameters and use case data only as a lower bound. Fits to the first 20 days of data determine a degenerate combination of the basic reproduction number, R0, and the mean time to removal from the infectious population, γ−1, with γ(R0 − 1)= 0.25(0.21) inverse days for NYC (Cook County). Equivalently, the initial doubling time was td = 2.8(3.4) days for NYC (Cook). The early fatality data suggest that both locations had infections in early February. I model the mitigation measures implemented in mid-March in both locations (distancing, quarantine, isolation, etc) via a time-dependent reproduction number Rt that declines monotonically from R0 to a smaller asymptotic value, R0(1 − X), with a parameterized functional form. The timing (mid-March) and duration (several days) of the transitions in Rt appear well determined by the data. With flat priors on model parameters and the lower bound from reported cases, the NYC fatality data imply 95.45% credible intervals of R0 = 2.6 − 2.9, social contact reduction X = 69 − 76% and infection fatality rate f = 1 − 1.5%, with 19 − 27% of the population asymptotically infected. The case data relative to daily deaths suggest that the reported case rate as a fraction of true case rate grew monotonically, reaching a plateau around April 20 for both NYC and Cook County; the models also suggest that the late-time NYC reported case rate was comparable to the true rate, while for Cook County it remained an underestimate. For Cook County, the fatality evolution was qualitatively different from NYC: after mitigation measures were implemented, daily fatality counts reached a plateau for about a month before tailing off. This is consistent with an SIR model that exhibits “critical slowing-down”, in which Rt plateaus at a value just above unity. For Cook County, the 95.45% credible intervals for the model parameters are not constrained by the case data and are much broader, R0 = 1.4 − 4.7, X = 26 − 54%, and f = 0.1 − 0.6% with 15 − 88% of the population asymptotically infected. Despite the apparently lower efficacy of its social contact reduction measures, Cook County has had significantly fewer fatalities per population than NYC, D∞ /N = 100 vs. 270 per 100,000. In the model, this is attributed to the lower inferred IFR for Cook; an external prior pointing to similar values of the IFR for the two locations would instead chalk up the difference in D/N to differences in the relative growth rate of the disease. I derive a model-dependent threshold, Embedded Image, for ‘safe’ re-opening, that is, for easing of contact reduction that would not trigger a second wave; for NYC, the models predict that increasing social contact by more than 20% from post-mitigation levels will lead to renewed spread, while for Cook County the threshold value is very uncertain, given the parameter degeneracies. The timing of 2nd-wave growth will depend on the amplitude of contact increase relative to Embedded Image and on the asymptotic growth rate, and the impact in terms of fatalities will depend on the parameter f.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This analysis used computing resources of the Fermi National Accelerator Laboratory (Fermilab), a U.S. Department of Energy, Office of Science, HEP User Facility. Fermilab is managed by Fermi Research Alliance, LLC (FRA), acting under Contract No. DE-AC02-07CH11359.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Addition of Section 4.1.1 including case data constraints on NYC models. Table 2, Figs. 3-6, 11-12 revised accordingly.

Data Availability

Based upon publicly available fatality data at the sites below.

https://nychealth/coronavirus

https://maps.cookcountyil.gov/medexamcovid19/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 28, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A “Tail” of Two Cities: Fatality-based Modeling of COVID-19 Evolution in New York City and Cook County, IL
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A “Tail” of Two Cities: Fatality-based Modeling of COVID-19 Evolution in New York City and Cook County, IL
Joshua A. Frieman
medRxiv 2020.08.10.20170506; doi: https://doi.org/10.1101/2020.08.10.20170506
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
A “Tail” of Two Cities: Fatality-based Modeling of COVID-19 Evolution in New York City and Cook County, IL
Joshua A. Frieman
medRxiv 2020.08.10.20170506; doi: https://doi.org/10.1101/2020.08.10.20170506

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)